Senl-215

N/A

Report date: 2024/07/23 17:59:07

Base Information

Drug NameSenl-215
Drug Alias NameSenl-215
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHebei Senlang Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Senlang Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A